B
16.78
-0.02 (-0.12%)
| Previous Close | 16.80 |
| Open | 16.80 |
| Volume | 682,454 |
| Avg. Volume (3M) | 533,250 |
| Market Cap | 919,241,216 |
| Price / Earnings (TTM) | 3.12 |
| Price / Book | 2.28 |
| 52 Weeks Range | |
| Earnings Date | 26 Mar 2026 |
| Diluted EPS (TTM) | -1.69 |
| Total Debt/Equity (MRQ) | 0.13% |
| Current Ratio (MRQ) | 24.62 |
| Operating Cash Flow (TTM) | -88.27 M |
| Levered Free Cash Flow (TTM) | -53.72 M |
| Return on Assets (TTM) | -13.84% |
| Return on Equity (TTM) | -27.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Bicara Therapeutics Inc. | Bullish | Bearish |
AIStockmoo Score
0.9
| Analyst Consensus | 4.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.90 |
|
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 11.65% |
| % Held by Institutions | 89.28% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Red Tree Management, Llc | 31 Dec 2025 | 3,170,509 |
| Tpg Gp A, Llc | 31 Dec 2025 | 3,010,425 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 31.00 (Citizens, 84.74%) | Buy |
| Median | 29.00 (72.83%) | |
| Low | 18.00 (Mizuho, 7.27%) | Hold |
| Average | 26.75 (59.42%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 17.16 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citizens | 29 Jan 2026 | 31.00 (84.74%) | Buy | 16.91 |
| Wedbush | 13 Jan 2026 | 30.00 (78.78%) | Buy | 17.53 |
| BTIG | 08 Jan 2026 | 28.00 (66.87%) | Buy | 16.56 |
| Mizuho | 18 Dec 2025 | 18.00 (7.27%) | Hold | 17.64 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| COHLHEPP RYAN | - | 17.51 | -3,631 | -63,579 |
| Aggregate Net Quantity | -3,631 | |||
| Aggregate Net Value ($) | -63,579 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 17.51 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| COHLHEPP RYAN | Officer | 25 Feb 2026 | Automatic sell (-) | 3,631 | 17.51 | 63,579 |
| COHLHEPP RYAN | Officer | 25 Feb 2026 | Option execute | 3,108 | - | - |
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 12 Jan 2026 | Announcement | Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook |
| 15 Dec 2025 | Announcement | Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 |
| 06 Dec 2025 | Announcement | Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |